Investigation and Prosecution of Those Individuals Responsible for

Crimes Against Humanity

29 September 2021  

The International Criminal Court

Office of the Prosecutor

Post Office Box 19519

2500 CM The Hague

The Netherlands  

And  

Ms. Karen Mosoti, or official replacement for the office of

Liaison Office of the International Criminal Court to the United Nations

866 United Nations Plaza

Suite 476

New York, NY, 10017

USA

212-486-1346/47/62  

Email: otp.informationdesk@icc-cpi.int  

Dear International Criminal Court and Prosecutor of the International Criminal Court, Mr. Karim Khan, and Ms. Karen Mosoti,  

The following signatories submit to the International Criminal Court (ICC) and the Office of the Prosecutor, this   Letter in Support of:  

(1)  The Joint Request for Investigation from the United Kingdom submitted by attorneys Melinda Mayne, Kaira S. McCallum (143/21), Slovakia submitted by attorneys Peter Weis, Marica Pirosikova, Erik Schmidt (133/21), France submitted by attorneys Patrice Lepiller, Raphael Cohen (271/21), and the Czech Republic submitted by attorney Tomas Nielsen (326/21) submitted to this Court on 12 August 2021.

(2)  The Sworn Affidavits of Drs/PhDs. Richard M. Fleming, Luc Montagnier, and Kevin McCairn submitted with this Joint Request.

(3)  Letter of Support by Nazi Concentration Camp Survivors Moshe Brown, Hillel Handler, and Vera Sharav submitted 20 September 2021.  

In each instance the material, affidavits, and evidence provided substantiate information demonstrating Crimes Against Humanity by the Perpetrators including but not limited to violations of:  

(1)  The 1947 Nuremberg Code

(2)  The 1964 Declaration of Helsinki

(3)  The 1967 International Covenant on Civil and Political Rights, and

(4)  The 1975 Biological Weapons Convention Treaty  

We call upon the ICC and the Office of the Prosecutor of the ICC, and the United Nations Liaison Office of the ICC, to forthwith accept the Joint Request for Investigation, the Sworn Affidavits, the Nazi Concentration Camp Survivors’ Letter of Support, and supporting documents and materials, and to begin the Investigation and Criminal Prosecution of those individuals identified in the submitted documents, and those individuals identified in the interrogatories, depositions and investigation of those so identified.

Sign this petition by going to this link: https://www.petitions.net/investigation_and_prosecution_of_those_individuals_responsible_for_crimes_against_humanity

Richard M Fleming, PhD, MD, JD    Contact the author of the petition

Go to Richard M Fleming’s website https://www.flemingmethod.com/

See also: https://peoplesworldwar.com/dr-richard-fleming-severe-criminal-violations/


More Information From Dr. Richard Fleming’s Website

DOCUMENTATION

     The following diagram shows how SARS-CoV-2 is passed from person to person through respiratory droplets. Once inside the body the virus will invade our cells and reproduce itself. In response to the virus our immune system will attack the invader launching first a response from T-cells designed to kill the cells infected with the virus and later an antibody response designed to kill the virus before it gets into another cell.

     This diagram also shows how too much of a good thing can cause harm to the body. When our VIRAL immune response, either because of other health problems we have (comorbidities) produce too much response OR because there is too much of the virus (e.g. vaccines) in our body; the outcome is INFLAMMATION and BLOOD CLOTTING [InflammoThrombotic Response – ITR] that can kill us (COVID-19).

     The document numbers listed on the diagram below match the numbered documents providing links to the research as well as other materials not only explaining these issues but also the Gain-of-Function (GoF) research responsible for the development of this man-made virus.

Figure 8(b).png
SARS-CoV-2: Documents 1720144145146147148153, 156, 163, 164, 165, 169170182, 193, 194, 199, 209, 210, 212, 213, 214.

InflammoThrombotic Response (ITR): Documents 181921333749.
 
Treatment Information & Immunity: Documents 406768,
69707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142151152161162168171172173174175176177178179180181183, 186, 187, 205, 206, 207, 208, 211.
 
Gain-of-Function (With HIV-gp120; PRRA & Prion-like Domain): Documents 7914151621222635363839414243444546474850545657160166184, 215.

BIOWEAPON: 5859606162.
 
Vaccines: Documents 12313243132515253555665.
143, 149150154155158159167185, 188, 189, 190, 191, 192, 195, 196, 197, 198, 200, 201, 202, 203, 204, 207, 

Enters Nucleus with DNA: Documents 101112636466157.
 
Antibody Dependent Enhancement of Virus: Documents 456167.

Neurologic – Central Nervous System – Brain: 823252728293034.
1. EUA Requirements by FDA

October 2020

2. Pfizer EUA document

December 10, 2020

3. Moderna EUA Document

December 17, 2020

4. SARS-CoV-1 Antibody Dependent Enchancement (ADE)

July 5, 2011

5. ADE shown in animals including primates

January 2, 2021

6. ADE (Osaka Paper) showing antibodies to NTD increase infectivity of SARS-CoV-2

December 18, 2020

7. Prion-like Domains

March 29,, 2020

8. Amyloid Precursor Proteins and Neurologic Disease

May 21, 2019

9. Amyloidosis and Prion Diseases

October 26, 2010

10. SARS-CoV-2 RT back into human DNA

December 13, 2020

11. Platlets and LINE-1 to Generate RNA-DNA Hybrids with Reverse Transcriptase

April 2018

12. Reverse Transcription Produces Mechanism for Long Term Survival and Recurrent Infections

January 9, 2019

13. Pfizer vaccines contains 13 billion mRNA repetitions in the low dose of 30-micrograms.

December 25, 2020

14. Baric & Zhengli Shi re-engineer the HKU4 spike to increase Corona Virus Infectivity. Gain-of-Function (GoF)

September 2015

15. SARS-CoV-2 Gain-of-Function Hall of Shame

October 1, 2020

16. Evidence that SARS-CoV-2 is not naturally evolved

July 1, 2020

17. South African Mutation of SARS-CoV-2

December 22, 2020

18. InflammoThrombotic Response (ITR)

August 18,2020

19. Massive Blood Clots Kill COVID Patients

August 18, 2020

20. Cryo-Electron Tomography of SARS-CoV-2 showing spike proteins

October 9, 2020

21. PRRA Superantigen increases inflammation

October 13, 2020

22. PRRA Insert essential for infection of human lung cells and brain

May 1, 2020

23. SARS-CoV-2 Spike protein crosses the blood brain barrier in mice study

December 16, 2020

24. Neurological adverse events associated with vaccines

June 2002

25. SARS-CoV-2 Invades Brain

November 30, 2020

26. Neuropilin-1binds to Furin (PRRA) Cleavage site to increase Infectivity.

November 13, 2020

27. Spike Protein Crosses BBB to Infect Brain

November 30, 2020

28. Fatal Invasion of Brain by SARS-CoV-2 Depends upon ACE2.

January 15, 2021

29. SARS-CoV-2 Interferes With Recognition of the Severity of Hypoxemia.

July 28, 2020

30. RNA can Behave like Prions.

July 1, 2020

31. Influenza mRNA Spreads Throughout Body and Found in Lungs, Brain, Heart for 14-days.

October 1995

32. Moderna mRNA Vaccine for Influenza Spreads Throughout Body.

March 24, 2017

33. How Immune Cells Cross the Blood-Brain Barrier.

February 4, 2019

34. Neuroinvasion, Encephalitis and Neuron Death with SARS-CoV-2.

January 19, 2021

35. Jean claude Perez § Luc Montagnier – COVID-19, SARS and Bats Coronaviruses Genomes Unexpected Exogenous RNA Sequences

May 29, 2020

36. Jean claude Perez § Luc Montagnier – COVID-19, COVID-19, SARS and Bats Coronaviruses Genomes Peculiar Homologous RNA Sequences 

July 7, 2020

37. Autopsy Findings of InflammoThrombotic Response (ITR) in Patients with COVID-19

JAugust 18, 2020

38. TMPRSS2 and Furin Both Essential for SARS-CoV-2 Infection of Cells.

July 23, 2020

39. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1

March 22, 2020

40. Treatment of SARS-CoV-2 & COVID-19.
February 8, 2021
41. Evidence of Gain-of-Function.

September 14, 2020

42. Gain-of-Function Hall of Shame.

October 1, 2020

43. Origins of SARS-CoV-2.

February 7, 2021

44. Genetic Structure of SARS-CoV-2.
October 16, 2020
45. Origins of SARS and PRRA.

August 12, 2020

46. The Corona Conspiracy.

October 2020

47. Probabilities of SARS-CoV-2 Origin.

November 12, 2020

48. The Fauci COVID-19 Dossier.

February 18, 2021

49. Primate studies show Inflammation in Brain & Lewy Bodies.

February 23, 2021

50. Patent for PRRA Furin Cleavage Site with Certain Patent Rights Owned by U.S. Governmnent (NIH).

May 29, 2007

51. Janssen (Johnson & Johnson) EUA Document.

February 26, 2021

52. Ad26 [J & J] Prior Studies Reveal Only Temporary Immunity.

July 18, 2012

53. The Coxsackie & Adenovirus Receptor (CAR).

June 8, 1999

54. Deleted Wuhan Databases.

February 23, 2021

55. CDC Document on Adenovirus Vaccines.

January 8, 2020

56. COVID-19 Vaccines and Brain Injury.

April 10, 2021

57. SARS-CoV-2 Accelerates Amyloid Formation.

April 12, 2021

58. SARS-CoV-2 Is an Unrestricted Bioweapon.

Released April 24, 2021

59. SARS-CoV-2 is a Sophisticated Lab Modification.

Released April 24, 2021

60. CNN Lies and Misinformation.

September 14, 2020

61. SARS-CoV-2 – A Scientific Discussion of Lab Origin.

March 25, 2021

62. Lethal Deception.

April 22, 2021

63. Reverse Transcription of SARS-CoV-2 in Human Cells.

March 29, 2021

64. Evidence in Support of SARS-CoV-2 (Viral)-Human Cell Chimers.

March 29, 2021

65. Rethinking Vaccine Safety.

June 24, 2021

66. SARS-CoV-2 Reverse Transcription (RT) Integration into Human DNA.

May 6 , 2021

67. Immunity to SARS-CoV-2 Independent of Severity of SARS-CoV-2/COVID-19 Infection.

June 4, 2021

68. Italian Treatment Recommendations.

March 20, 2021

69. Commenting on Chloroquine.

March 2, 2020

70. Interleukin-6 (IL-6) levels.

April 11, 2020

71. Hydroxychloroquine (HCQ).

April 14, 2020

72. ACEI & ARBs.

May 8, 2020

73. Anti-virals.

January 27, 2020

74. Masks.

April 6, 2020

75. IL-6 Inhibitors.

May 29, 2020

76. Quantitative Nuclear Imaging of Disease.

July 24, 2019

77. Treating QTc Prolongation.

June 25, 2009

78. Hydroxychloroquine better than Chloroquine.

March 14, 2020

79. Nuclear Imaging of Infections.

January 1, 2008

80. Toll-like Receptors.

January 1, 2008

81. Nebulized Azithromycin.

2019

82. Mesenchymal Stem Cells.

February 18, 2020

83. TMPRSS2 and Furin Cleavage Receptors.

May 20, 2020

84. Hydroxychloroquine and Azithromycin.

April 1, 2020

85. Cuban Interferon.

March 13, 2020

86. IL-6 levels Predict Respiratory Failure.

April 1, 2020

87. Vitamin D and Steroids.

April 2020

88. Quantifying Changes in Disease & Treatment Outcomes.

January 17, 2020

89. Ivermectin Protects Nuclear Pore Complex (NPC).

March 29, 2020

90. Convalescent Plasma.

April 3, 2020

91. Multiple Drug Considerations.

May 12, 2020

92. Early Results of Convalescent Plasma.

April 13, 2020

93. N-95 Masks.

February 12, 2020

94. Face Masks in Symptomatic Individuals.

April 10, 2020

95. Decreasing Ventilator Tidal Volume (TV) to Reduce Deaths.

May 4, 2000

96. Lopinavir-Ritonavir Not Successful.

May 7, 2020

97. Reduce TV on Ventilators for Patients with ARDS to Reduce Deaths.

July 22, 2004

98. Remdesivir.

April 10, 2020

99. ACEI and ARBs in the Patients with Heart Disease.

May 1, 2020

100. Multiple Treatment Considerations.

April 28, 2020

101. Rethinking ACEI and ARBS.

April 23, 2020

102. Simple Ventilator & Breathing Terms for Students Using Ventilators.

2008

103. Prone Positioning of Patients Saves Lives.

June 6, 2013

104. Prone Positioning of Patients.

April 8, 2020

105. Remdesivir.

June 2020

106. Treating the InflammoThrombotic Response (ITR).

May 6, 2020

107. SARS-CoV-2 Genome.

May 4, 2020

108. Neutralizing Antibodies.

May 18, 2020

109. Transmission of SARS-CoV-2.

April 15, 2020

110. Centers for Disease Control (CDC) & Emergency Use Authorization (EUA).

April 13, 2020

111. ACEI and ARBs in the Patients with Hypertension (High Blood Pressure).

April 22, 2020

112. Nebulized Antibiotics.

June 2015

113. Nebulized Antibiotics with Lung Disease.

April 1, 2016

114. Thinking About the Pharmacodynamics of Antibiotics.

Deember 12, 2011

115. Immune Response and Various Antibiotics.

December 2015

116. Azithromycin and Zika Virus.

December 13, 2016

117. Doxycycline.

May 9, 2020

118. Aminoquinolines.

April 7, 2020

119. Chloroquine Zinc Ionophore.

October 1, 2014

120. Transmembrane protease serine 2 (TMPRSS2).

April 16, 2020

121. Hydroxychloroquine – NOT alone.

April 16, 2020

122. Primaquine and Newcastle Virus.

October 1974

123. Convalescent Plasma and Viral Infections.

January 1, 2015

124. Neutralizing Antibodies.

March 15, 2020

125. Esmolol for QTc Prolongation.

March 13, 2020

126. Drugs to Avoid with Long QT Syndrome.

April 26, 2013

127. Tocilizumab.

2020

128. Tocilizumab is Effective for ITR.

April 14, 2020

129. Tocilizumab Treatment of COVID-19 Respiratory Failure.

March 27, 2020

130. Tocilizumab and Castleman Disease.

November 2008

131. Janus Kinases.

November 30, 2004

132. Interferon Combination Therapies.

May 8, 2020

133. QTc Prolongation and Tachycardia with Ventolin (Albuterol).

June 28, 2016

134. Chloroquine Reduces Interleukins.

November 29, 2005

135. Zinc (Zn++) Ionophore.

April 9, 2020

136. Interleukin-6 (IL-6) and Steroid Resistance.

December 26, 2012

137. Inhaled Corticosteroids.

March 8, 2010

138. Inhaled Methylprednisolone.

March 30, 2020

139. Innate Immunity.

June 17, 2014

140. Clindamycin and TMPRSS2.

February 18, 2020

141. Heparin Inhibits S1 Spike Protein Attachment to Heparin Binding Protein Site of Regional Binding Domain (RBD).

June 6, 2020

142. Measuring PCR & The Importance of Providing Successful Treatments – Fleming Treatments Recognized Internationally.

July 1, 2021

143. Graphene Oxide Disrupt SARS-CoV-2 Ability to Infect.

May 14, 2021

144. 30,091SARS-CoV-2 Nucleotide Bases.

July 14, 2021

145. The SARS-CoV-2 Virus.

June 2020

146. Recovery of Wuhan Lab Data.

June 22, 2021

147. 283 SARS-CoV-2 Case Information.

March 31, 2020

148. SARS-CoV-2-WA/CDC.

July 29, 2020

149. COVID-19 Vaccine Associated Parkinson’s Disease, A Prion Disease Signal in the UK Yellow Card Adverse Event Database.

July 18, 2021

150. Pfizer UK Yellow Card Adverse Event Data.

June 30, 2021

151. Unexpected SARS-CoV-2 RNA Sequences.

May 30, 2020

152. Mask Analysis of SARS.

August 7, 2017

153. Fibonacci Analysis of SARS-CoV-2 Variants and Vaccine mRNA Spikes.

June 30, 2021

154. COVID-19 RNA Based Vaccines and Prion Disease.

January 18, 2021

155. Review of COVID Vaccines and Risk of Adverse Events Including Neurologic Disease.

April 10, 2021

156. Mullis PCR Patent.

July 28, 1987

157. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues.

May 6, 2021

158. Shedding is defined by FDA, HHS, and the Center for Biologics Evaluation and Research.
(Look at the foot notes at the bottom of page 9).
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products

January 2020

159. SARS-CoV-2 Drug Vaccine Biologics are Gene Therapy According to FDA definition.
July 25, 2018
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy

160. Daszak & Zhengli build a Gain-of-Function Coronavirus that inhibits protective human immune response. Paid for by NIAID.

May 11, 2016

161. Natural IgG and IgA Immunity Following Infection with SARS-CoV-2.

May 7, 2021

162. T-cell Receptor (TCR) Immunity to SARS-CoV-2 Following Infections with Influenza or Cytomegalovirus (CMV).

June 23, 2021

163. SARS-C0V-2 Isolation Sequence & Primers.

April 12, 2020

164. Original Chinese Patients with SARS-CoV-2.

January 24, 2020

165. Appendix for # 164.

January 24, 2020

166. SARS-CoV-2 Prion-like Domain (PLD) Increases Infectivity of this Virus.

March 29, 2020

167. Patients are NOT Receiving Adequate Informed Consent.

December 4, 2020

168. Evidence of Long Term Durable Natural Immunity to SARS-CoV-2 Following Infection.

July 20, 2021

169. SARS-CoV-2 Bayesian Analysis Concludes SARS-CoV-2 Was NOT Natural BUT Laboratory Developed.

January 29, 2021

170. House Foreign Affairs Committee Report Minority Staff. Origins-of-COVID-19 Report.

August 2021

171. Harm Caused by Excluding Family Visitation.

January 11, 2021

172. Multiple Benefits to Patients with Family Visitation.

September 15, 2020

173. Supportive Evidence for Family ICU Visitation.

November 2011

174. The Importance of Family in Pediatric Cases.

May 6, 2020

175. Impact of Family Presence in the Healthcare Setting.

Spring 2014

176. Let Families into Intensive Care Units (ICUs).

March 6, 2016

177. The Family Needs of Intensive Care Unit (ICU) Patients.

March 25, 2019

178. Patients & Families of Intensive Care Unit (ICU) Patients.

April 6, 2018

179. Care & Caring in the Intensive Care Unit (ICU).

June 2016

180. Hospital Systems Have Chosen the Fear for Us.

October 21, 2020

181. Substantial Evidence Suggests Parental Visitation to Neonates (newborns) in Neonatal Intensive Care Units (NICU) Should NOT Change.

August 8, 2020

182. Aerosol Transmission of SARS-CoV-2?

August 7, 2020

183. Natural Immunity to Delta Variant Provides Stronger and Longer Lasting Immunity than Pfizer Vaccine.

August 25, 2021

184. Canadian Emails Re: Early Wuhan SARS-CoV-2 Genetic Modifications.

August 28, 2021

185. Both SARS-CoV-2 and the Vaccines Increase Risk of InflammoThrombotic Response (ITR) Disease (COVID-19).

August 25, 2021

186. The Importance of the Innate T-Cell Immune System in Children.

July 26, 2021

187. Antibodies to Spike Protein Can Cause Severe Acute (sudden) Lung Disease.

February 21, 2019

188. Pfizer Vaccine Interferes with Tdap Vaccine.

July 25, 2021

189. SARS-CoV-1 Vaccine Leads to Lung Disease.

April 20, 2012

190. Moderna Patent Shows Effect on Innate Immune Response (pp. 24 & 24).

July 7, 2020

191. Moderna Patent – Publication

November 12, 2020

192. Pfizer, Moderna & Janssen Drug Vaccines Cause More Harm than Good.

August 25, 2021

193. Beta (B.1.351) Variant Emerges in South Africa.

December 22, 2020

194. Morbidity and Mortality Weekly Report (MMWR) Reports that 74% of People with Delta (B.1.617.2) Variant in Massachusetts are Fully Vaccinated.

August 6, 2021

195. Israeli Data Shows Good Protection with Pfizer Two Dose Vaccinated People for Alpha (B.1.1.7) Variant.

May 15, 2021

196. Delta Variant (B.1.617.2) Surging in Israel In Spite of Pfizer Two Dose Vaccinations.

July 31, 2021

197. German Outbreak of Alpha (B.1.1.7) Variant Following Pfizer Two Dose Vaccinations.

August 2021

198. The Importance of Recognizing the Limitations of Spike Protein Regional Binding Domain (RBD) [e.g. nucleotide bases 318-510] Drug Vaccines. Another lesson forgotten: “with distinct genotypes”.

July 2005

199. Morbidity and Mortality Weekly Report (MMWR). U.S. HHS Knows About SARS-CoV-2 Variants.

January 22, 2021

200. Pfizer Vaccine Shown to Reduce Innate T-Cell Response.

October 22, 2020

201. Moderna (mRNA-1273) Vaccine Fails to Elicit Th2 Innate Immune Response Critical for B-Cell (antibody) Proliferation (increase) and Differentiation (Specific Antibody Production).

July 28, 2020

202. AstraZeneca (ChAdOx1 nCoV-19) Vaccine Results in Multiple Cebral (Brain) Venous (Veins) Thrombosis (Blood Clots).

September 2021

203. Chinese Drug Vaccine for SARS-CoV-1.

January 1, 2007

204. Pfizer Drug Vaccine Reprograms, in Some Instances Weakening, the Human Innate Immune Response to Multiple Pathogens.

May 6, 2021

205. Primaquine Inhibits Protein Biosynthesis (i.e. mRNA to Protein Translation). It’s more than just an anti-malarial.

January 26, 1972

206. Antibodies Produced Against Innate T-Cell Interferon Increases the Risk of InflammoThrombotic Response (ITR) Pulmonary Disease (COVID-19).

October 23, 2020

207. Antibody Dependent Enhancement (ADE) Antibodies are a Potential Risk Associated with Drug Vaccine Biologics.

August 16, 2021

208. Interferon-gamma Critical to Innate Immunity.

August 1983

209. The Glycan Gate & The Sialic Acid Raft Receptor.

August 19, 2021

210. Sialic Acid Raft Recptor (Neu5Ac) Emerging as Interface Between Infectious Disease, Biological Chemistry, and Nanoscience.

February 5, 2021

211. Ions Including Ca+2, Mg +2, and Zn+2 and Their Roles as Cofactors in Immunity.

June 2018

212. Baric Makes Complete Recombinant SARS Coronavirus.

October 28, 2003

213. Patent Links Baric’s Work with Transmissible Gastroenteritis Virus (TGV) and Recombinant Production of Coronavirus. Paid for by NIH Grants.

October 9, 2007

214. Intercept Newsroom “Understanding Risk Bat Coronavirus Emergence Grant Notice”.

September 2021

215. Method and Composition Patent for Chimeric Coronaviruses and Spike Proteins. NIH Grant U54AI057157.

February 6, 2018

The bottom portion of this page has been shared from https://www.flemingmethod.com/documentation

By admin